Back to User profile » Dr Arshad M Khanani

Papers published by Dr Arshad M Khanani:

Cooling Anesthesia for Intravitreal Injections – A Review

Chandrasekaran PR, Aziz AA, Khan H, Khanani AM

Clinical Ophthalmology 2023, 17:197-207

Published Date: 13 January 2023

Macular Telangiectasia Type 2: A Comprehensive Review

Kedarisetti KC, Narayanan R, Stewart MW, Reddy Gurram N, Khanani AM

Clinical Ophthalmology 2022, 16:3297-3309

Published Date: 10 October 2022

Cooling Anesthesia for Intravitreal Injection: Results of the Prospective Open-Label, Dose-Ranging COOL-1 Trial

Chao DL, Rinella NT, Khanani AM, Wykoff CC, Kim GH

Clinical Ophthalmology 2021, 15:4659-4666

Published Date: 10 December 2021

Angiopoietins as Potential Targets in Management of Retinal Disease

Khanani AM, Russell MW, Aziz AA, Danzig CJ, Weng CY, Eichenbaum DA, Singh RP

Clinical Ophthalmology 2021, 15:3747-3755

Published Date: 4 September 2021

Retrospective Study of Ellipsoid Zone Integrity Following Treatment with Intravitreal Ocriplasmin (OZONE Study)

Drenser KA, Pieramici DJ, Gunn JM, Rosberger DF, Kozma P, Fineman MS, Duchateau L, Khanani AM

Clinical Ophthalmology 2021, 15:3109-3120

Published Date: 16 July 2021

Predictors of Early Diabetic Retinopathy Regression with Ranibizumab in the RIDE and RISE Clinical Trials

Singer M, Liu M, Schlottmann PG, Khanani AM, Hemphill M, Hill L, Tuomi L, Haskova Z

Clinical Ophthalmology 2020, 14:1629-1639

Published Date: 17 June 2020

Five-year outcomes of intravitreal drug therapy for neovascular age-related macular degeneration in eyes with baseline vision 20/60 or better

Khanani AM, Gahn GM, Koci MM, Dang JM, Brown SM, Hill LF

Clinical Ophthalmology 2019, 13:347-351

Published Date: 13 February 2019

Endophthalmitis rates among patients receiving intravitreal anti-VEGF injections: a USA claims analysis

Kiss S, Dugel PU, Khanani AM, Broder MS, Chang E, Sun GH, Turpcu A

Clinical Ophthalmology 2018, 12:1625-1635

Published Date: 30 August 2018